Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01189643 · ClinicalTrials.gov registry record · Early Phase 1
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
A Early Phase 1 study of Sarcoma and Desmoplastic Small Round Cell Tumor (DSRCT), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01189643 is a Early Phase 1 study of Sarcoma and Desmoplastic Small Round Cell Tumor (DSRCT) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01189643, a Early Phase 1 study of Sarcoma and Desmoplastic Small Round Cell Tumor (DSRCT), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.
Conditions Studied
Interventions
- DRUG irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-08 |
| Est. Completion | 2026-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01189643
The ClinicalTrials.gov registry entry for NCT01189643 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator is the first listed.
NCT01189643 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01189643 about?
NCT01189643 is a clinical study titled "Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor". This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has ...
What is the current status of trial NCT01189643?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2010-08. Estimated completion is 2026-08.
What conditions does trial NCT01189643 study?
This clinical trial studies the following conditions: Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT).
What interventions are being tested in trial NCT01189643?
The interventions under investigation include: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator (DRUG).
Who is sponsoring clinical trial NCT01189643?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01189643 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
ACTIVE NOT RECRUITING · Early Phase 1
-
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
ACTIVE NOT RECRUITING · Early Phase 1
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.